AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

RecruitingPhase 1, Phase 2Ages 2 Years - 18 YearsAllShionogi
💬

In plain words

What the trial is, and whether it could suit you

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive opioids.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: Disease Characteristics * Participants with cancer or non-cancer pain who are receiving (or who are about to receive) acute or chronic treatment with opioids. * Participants with either newly diagnosed constipation, a history of constipation treated with laxatives, or are expected to develop constipation after opioid treatment. * Able to remain in the clinic for blood sampling for at least 12 hours following the first study intervention dose and are able to return for blood sampling at the 24-hour time point. Weight * Body mass index within approximately the 3rd to 97th percentile for their age according to the World Health Organization Child Growth Standards. Exclusion Criteria: Medical Conditions * History of a gastrointestinal (GI) neoplasm or an ongoing GI-related issue or any recent (within last 1 year) or planned GI tract surgery. * Signs or symptoms of GI obstruction or participants with recurrent obstruction who may be at increased risk of GI perforation. * Inability to eat/swallow or have need of a nasogastric tube. * No bowel movements reported for 7 consecutive days at the time of obtaining informed consent or on the initial day of study intervention administration (Study Day 1). * History of more than 1 week of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 neutropenia or thrombocytopenia with clinical sequelae. * Participants who need mechanical ventilation. * Severe CTCAE Grade 3 or above hepatic or renal impairment including end-stage renal disease requiring hemodialysis, as determined by the investigator. * Progressive neurological disorders or potential disruption to the blood-brain barrier (for example, primary brain malignancies, central nervous system metastases, active multiple sclerosis, etc.) considering the risk of opioid withdrawal or reduced analgesia. Prior/Ongoing Medications * Currently receiving the first cycle of chemotherapy. * Previously received naldemedine. Other Exclusions \- Positive pregnancy test for females of childbearing potential. Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
💊

What it tests

  • Naldemedine
📍

Where

16 sites
University Center Mother Theresa , Hospital - Onco-hematology department
Tirana, Albania
Yeolyan Hematology. , and Oncology Center -
Yerevan, Armenia
CHU Saint-Pierre Clinical Trials Unit
Brussels, Belgium
Universitair Ziekenhuis Brussel (UZBrussel) - Department of Anesthesiology and Perioperative Medicine
Brussels, Belgium
University Hospitals Leuven Pediatrisch hemato-oncology
Leuven, Belgium
University Clinical Hospital , Mostar
Mostar, Bosnia and Herzegovina
Chu de Caen
Caen, France
Hôpital Béclère Service de Pédiatrie Centre de Référence des Maladies Héréditaires du Métabolisme Hépatique (CRMHMH)
Clamart, France

…and 8 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy